Loading
A phase 2 trial of Palbociclib, Cetuximab and Fulvestrant in head and neck squamous cell carcinoma, run by Pfizer, active and no longer recruiting.
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies is a phase 2 interventional study registered as NCT05226871 by Pfizer, with 35 participants enrolled, started 2022-07-07 and due to reach its primary completion in 2029-12-31. Interventions recorded: Palbociclib, Cetuximab, Fulvestrant and Letrozole.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Palbociclib, CDK4/6 inhibitors, UCSF Helen Diller Family Comprehensive Cancer Center, Pfizer (incl. Seagen) and the tag pipeline.
Shares Fulvestrant, CDK4/6 inhibitors, Pfizer (incl. Seagen) and the tag pipeline.
Shares Palbociclib, Fulvestrant and the tag pipeline.
Shares Palbociclib, CDK4/6 inhibitors, Pfizer (incl. Seagen) and the tag pipeline.
Shares CDK4/6 inhibitors, UCSF Helen Diller Family Comprehensive Cancer Center, Pfizer (incl. Seagen) and the tag pipeline.
Shares Fulvestrant, UCSF Helen Diller Family Comprehensive Cancer Center and the tag pipeline.
Shares Palbociclib, Fulvestrant, CDK4/6 inhibitors and the tag pipeline.
Shares CDK4/6 inhibitors, UCSF Helen Diller Family Comprehensive Cancer Center, Pfizer (incl. Seagen) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/